-
Phase I-II first-in-human clinical study of intraputamenal CDNF in Parkinson’s disease: Exploratory PET imaging endpoints of the 12-month treatment period
-
Phase I-II first-in-human clinical trial of intraputamenal CDNF in Parkinson’s disease: Exploratory fluid-based biomarker endpoints of the 12-month treatment period
-
Phase I-II first-in-human clinical trial of intraputamenal CDNF in Parkinson’s disease: Topline results of the six-month double-blind placebo-controlled main study and the six-month active treatment extension study
-
Phenotype of Parkinson’s Disease in African Americans Using NIH Toolbox Motor Measures
-
Phenotypic analysis of subjects with homozygous and compound heterozygous PANK2 mutations in a single extended pedigree from the Dominican Republic (DR) PKAN cohort
-
Phenotypic heterogeneity in Chinese dystonia patients with KMT2B variants
-
Phenotyping spasticity-associated tonic spasms: implications for therapy
-
Photophobia and Progressive Supranuclear Palsy
-
Physical Therapy and Deep Brain Stimulation in Parkinson Disease: A Pilot Randomized Controlled Trial
-
Physical Therapy Role with Differential Diagonosis and Treatment with Dizziness and Multiple System Atrophy: A Case Study
- « Previous Page
- 1
- …
- 103
- 104
- 105
- 106
- 107
- …
- 149
- Next Page »